

# 中国生物医药：现状与前景

---

## **Chinese Biopharmaceutical Industry: Current State and Future Development**

**By: Jim J. Zhang, Ph.D.**

**Publisher: JZMed, Inc.**

**August, 2010**

## Table of Contents

<b>Scope of the Report</b> .....	<b>2</b>
<b>About Author</b> .....	<b>3</b>
<b>Executive Summary</b> .....	<b>13</b>

Current state of Chinese biopharma industry: Company, product and market  
Current capability of Chinese biopharma industry in R&D and manufacturing  
Biopharma outsourcing opportunities in China  
Future outlook of Chinese biopharma industry

### **Chapter One: Current State of Chinese Biopharma Industry: Company, Product and Market** .....

**21**

Summary .....	22
1.1 Introduction .....	24
1.2 Biopharma industry is booming in China .....	26
1.3 Structural analysis of Chinese biopharma industry .....	29
1.3.1 An overview of current state of Chinese biopharma industry .....	29
1.3.2 Classifications of Chinese biopharma companies in all categories .....	31
1. Manufacturing focused companies .....	36
2. R&D focused companies .....	37
3. Professional biopharma outsourcing service providers .....	38
1.3.3 In-depth analysis of the current state of Chinese biopharma industry .....	39
1.4 Current state of biologic products made by Chinese companies .....	43
1.5 Current market values of Chinese biopharma industry .....	57
1.5.1 China's total spending on biologic products .....	57
1.5.2 Current market value of Chinese biopharma industry .....	58
1.5.3 Comparison with global biopharma market .....	62
1. Current global biopharma market value .....	62
2. Current global market value of therapeutic proteins .....	63
3. Current global market value of therapeutic MAbs .....	65
1.5.4 Chinese vaccine market value .....	66
1. Current market value of vaccines in China .....	66
2. Chinese vaccine industry and market are promoted and accelerated by the entrance of world major pharma companies .....	69
a. Major pharma companies developing and manufacturing vaccines in China .....	69
b. Foreign biopharma companies marketing their vaccine products in China .....	71
3. Comparison of Chinese vaccine market with global vaccine market .....	72

### **Chapter Two: Current Capability of Chinese Biopharma Industry in R&D and Manufacturing** .....

**74**

Summary .....	75
2.1 Introduction .....	77
2.2 R&D capability of Chinese biopharma companies .....	78
2.2.1 Barriers retarding Chinese biopharma companies to gain R&D capability in biologic drug development .....	78
2.2.2 Companies possessing capability of conducting R&D of innovative biologic drugs .....	80
2.2.3 Types of innovative biologic drugs under development .....	82
2.2.4 R&D activities on biologic drugs in Chinese biopharma companies: therapeutic focus, mechanism of action and development stages .....	83
1. New recombinant protein drugs under development .....	83
2. New vaccines under development (including therapeutic vaccines) .....	86
3. New antibody drugs under development .....	87
4. New peptide-based drugs under development .....	88
5. Other R&D activities currently focused on by Chinese biopharma companies .....	89
2.2.5 Structure of R&D team of Chinese biopharma companies and their R&D spending level .....	91
2.2.6 Collaborations of Chinese biopharma companies with experienced foreign counterparts .....	93
2.2.7 Where the current R&D capability of Chinese biopharma companies stands in the world biopharma industry .....	94
1. Comparison with Western biopharma industry .....	94
2. Comparison with Indian biopharma industry .....	96
2.3 Manufacturing capability of Chinese biopharma companies .....	99
2.3.1 Classification of key steps in upstream and downstream of a biomanufacturing process and challenges in each stage .....	99
2.3.2 Strengths and weakness of Chinese biopharma companies in bio-manufacturing .....	100
2.3.3 Capability of Chinese biopharma companies in manufacturing of MAb drugs .....	105
2.3.4 Chinese biopharma companies' manufacturing capability is rapidly improved by forming alliance or collaborating with experienced multinational companies: Case studies .....	105
2.3.5 Current manufacturing capacity of Chinese biopharma companies .....	107
2.3.6 Where the current manufacturing capability and capacity of Chinese biopharma industry stand in the world biopharma industry .....	109
 <b>Chapter Three: Biopharma Outsourcing Opportunities in China .....</b>	 <b>112</b>
Summary .....	113
3.1 Introduction .....	115
3.2 Chinese biopharma companies providing outsourcing service .....	116
3.3 Service capability of Chinese bio-CROs and bio-CMOs .....	118

3.4 Current market size of biopharma outsourcing in China and comparison with global biopharma outsourcing market -----	127
3.4.1 Current market value of biopharma outsourcing in China -----	127
3.4.2 Comparison with global biopharma outsourcing market value -----	129
3.5 Examples of Western biopharma companies outsourcing in China -----	136
3.6 Where China's current service capability in biopharma outsourcing stands in the global biopharma outsourcing industry: Case studies and comparison with foreign bio-CROs/bio-CMOs -----	137

**Chapter Four: Future Outlook of Chinese Biopharma Industry ----- 139**

Summary -----	140
4.1 Introduction -----	142
4.2 Analysis of China's overall strength and weakness in biopharma industry and comparison with its international counterparts -----	144
4.3 Future growth drivers for Chinese biopharma industry -----	146
4.3.1 Current environment is favoring the development of biopharma industry in China -----	146
4.3.2 Development of Chinese biopharma industry is promoted and accelerated by increasing VC investments -----	148
4.3.3 Experienced multinational biopharma companies are racing to enter Chinese market and promoting the Chinese biopharma industry -----	150
4.3.4 Chinese government's support and determination to develop biopharma industry in China -----	150
4.4 Analysis of global competitive landscape facing Chinese biopharma companies -----	152
4.4.1 China's own competitive advantages in biopharma industry -----	152
4.4.2 Rising demand for global biopharma outsourcing service provides China with great opportunities -----	153
4.4.3 China's opportunity in antibody drug market -----	153
4.4.4 Current competitive landscape of Indian biopharma industry -----	155
4.4.5 Indian and Chinese biopharma companies are collaborating to enter global biosimilar market together -----	156
4.5 Penetration of single-use, disposable bio-manufacturing equipment into Chinese biopharma industry -----	157
4.6 Development of new biotechnologies and therapeutics in China -----	158
4.6.1 RNA interference and microRNA research in China -----	158
4.6.2 Stem cell research in China -----	159
1. Current market size of stem cell research in China -----	161
2. Comparison with global stem cell market -----	161
3. Examples of stem cell research in China -----	162
4.7 Future development of Chinese biopharma outsourcing service industry -----	165
4.8 Analysis of future growth resistors for Chinese biopharma industry -----	169
4.8.1 Quality issues currently still existing in Chinese biopharma industry --	169
4.8.2 Difficulties Chinese biopharma companies will face in developing innovative biologics as well as biogenerics -----	170
4.9 Forecast of future development of Chinese biopharma market -----	171

4.9.1	Growth forecast of overall biopharma market in China -----	171
4.9.2	Growth forecast of therapeutic MAb market in China -----	172
4.9.3	Growth forecast of recombinant protein drug market in China -----	173
4.9.4	Growth forecast of vaccine market in China -----	174
4.9.5	Comparison with the future growth potential of global vaccine market -	175

**Company Profile ----- 176**

Selection of top 100 best biopharma companies in China -----	177
Selection criteria -----	177
Areas examined -----	177
List of selected top 100 best biopharma companies in China -----	178

**Index ----- 280**

Foreign biopharma companies that have activities in China -----	281
---	-----

**Appendix ----- 282**

Appendix I. Summary of biologic products produced by Chinese biopharma companies -----	283
Appendix II. Summary of novel biologic drug candidates in the development pipelines of selected top biopharma companies in China -----	293
Appendix III. Research methodology -----	298
Appendix IV. About JZMed -----	299

**List of Tables**

Table 1. Examples of biotech clusters in Chinese cities -----	27
Table 2. Current structural composition of Chinese biotech industry -----	30
Table 3. Selected top 100 best biopharma companies in China -----	32
Table 4. Geographic display of Chinese biopharma companies -----	36
Table 5. Structural composition of manufacturing-focused Chinese biopharma companies -----	37
Table 6. Structural composition of Chinese biopharma industry -----	39
Table 7. Major Chinese pharma companies having biological programs (Including detail of their programs) -----	42
Table 8. List of Chinese biopharma companies manufacturing vaccines -----	46
Table 9. List of Chinese biopharma companies manufacturing recombinant interferons -----	50
Table 10. List of Chinese biopharma companies manufacturing recombinant interleukins -----	51
Table 11. List of Chinese biopharma companies manufacturing recombinant growth factors -----	52
Table 12. List of major erythropoietin (EPO) manufacturers in China -----	53
Table 13. List of Chinese biopharma companies manufacturing therapeutic MABs ---	55
Table 14. China's current total spending on biologic products and its growth history -----	58

Table 15. Current market value and growth history of Chinese biopharma industry --	59
Table 16. Current market value and growth history of therapeutic MAb drugs in China -----	61
Table 17. Current market value and growth history of global biopharma products ----	62
Table 18. Current market value, growth history and future growth forecast of global protein drugs -----	63
Table 19. Current market value, growth history and future growth forecast of global MAb drugs -----	65
Table 20. Current market value and growth history of vaccines in China -----	66
Table 21. Current market size and growth history of global vaccine market -----	72
Table 22. List of biopharma companies in China that have R&D capability -----	81
Table 23. Distributions of the number of innovative biologic drugs in various development stages in the pipelines of Chinese biopharma companies ----	83
Table 24. List of new recombinant protein drugs currently under development in China -----	84
Table 25. List of new vaccines currently under development in China -----	87
Table 26. List of new therapeutic MAbs currently under development in China -----	88
Table 27. List of new peptide drugs currently under development in China -----	88
Table 28. Chinese companies developing new delivery technologies for biologic drugs -----	90
Table 29. Chinese companies developing oligonucleotides for therapeutic or diagnostic use -----	90
Table 30. Comparison of a Chinese biopharma company with its Indian counterpart -----	98
Table 31. Classification of manufacturing steps of a bio-process -----	99
Table 32. Key manufacturing capability of Chinese biopharma companies -----	101
Table 33. Capability of Chinese biopharma companies in upstream processing -----	103
Table 34. Capability of Chinese biopharma companies in downstream processing --	104
Table 35. General manufacturing capacity of Chinese biopharma companies for protein-and MAb-based drugs -----	108
Table 36. Current manufacturing capacity of some representative Chinese biopharma companies -----	108
Table 37. Comparison of current manufacturing capability and capacity between world biopharma industry and Chinese biopharma industry (for protein-based and MAb-based drugs) -----	110
Table 38. List of professional biopharma outsourcing service providers in China ---	116
Table 39. Service capability of Chinese biopharma companies in upstream process -	118
Table 40. Service capability of Chinese biopharma companies in downstream process -----	121
Table 41. List of Chinese biopharma companies providing custom synthesis and/or manufacturing service of peptides -----	123
Table 42. List of Chinese biopharma companies providing service in nucleic acid research (DNA or RNA related) -----	124
Table 43. List of Chinese biopharma companies providing service of protein conjugates, MAb isotope labeling, biomarker analysis, vaccine clinical trial, siRNA labeling and siRNA library synthesis -----	126

Table 44. Current market values of Chinese biopharma outsourcing and biogeneric API industries -----	129
Table 45. Current market value and growth history of global bio-CMO industry ---	130
Table 46. Market share of global bio-CMO sector in the total global pharma CMO industry -----	131
Table 47. Current market values, growth history and future growth forecast of Chinese, Indian and global biogeneric API markets -----	135
Table 48. Comparison of technical capability in biopharma industry between China and the US -----	145
Table 49. List of representative venture capital investors in China -----	148
Table 50. List of biotech companies in China focusing on stem cell research -----	161
Table 51. Comparison of stem cell markets between China and the globe -----	162
Table 52. Forecasted market growth of Chinese biopharma industry -----	172
Table 53. Forecasted market growth of Chinese therapeutic protein market -----	173
Table 54. Forecasted market growth of Chinese vaccine market -----	174
Table 55. Future growth forecast of global vaccine market -----	175

### List of Figures

Figure 1. Analysis of structural compositions of Chinese biotech industry -----	30
Figure 2. Graphic display of structural composition of manufacturing-focused Chinese biopharma companies -----	38
Figure 3. Graphic display of current structural composition of Chinese biopharma industry -----	39
Figure 4. Types of biologic products China is currently able to produce -----	44
Figure 5. Types of vaccines Chinese biopharma companies are currently producing -----	46
Figure 6. Types of therapeutic recombinant proteins Chinese biopharma companies are currently producing -----	48
Figure 7. Types of blood products Chinese biopharma companies are currently producing -----	54
Figure 8. Types of therapeutic MAb Chinese biopharma companies are currently producing -----	54
Figure 9. Growth trend of China's total spending on biologic products -----	58
Figure 10. Growth trend of total output of Chinese biopharma industry -----	59
Figure 11. Structural analysis of current composition of Chinese biopharma market --	60
Figure 12. Growth trend of Chinese-made biologic drugs marketed overseas -----	60
Figure 13. Growth trend of Chinese therapeutic MAb market -----	61
Figure 14. Growth trend of global biopharmaceutical market -----	63
Figure 15. Growth trend of global therapeutic protein market -----	64
Figure 16. Geographic distribution of global market of therapeutic proteins -----	64
Figure 17. Growth trend of global therapeutic MAb market -----	65
Figure 18. Growth trend of Chinese vaccine market -----	67
Figure 19. Growth trend of global vaccine market -----	73
Figure 20. Key barriers retarding Chinese biopharma companies to gain capability in developing therapeutic MAb -----	78

Figure 21. Distribution of innovative biologics in the pipelines of Chinese biopharma companies -----	82
Figure 22. Distributions of innovative biologic drug candidates in various development stages in Chinese biopharma companies -----	83
Figure 23. Analysis of current global demands for biopharma outsourcing service --	128
Figure 24. Growth trend of global bio-CMO industry -----	130
Figure 25. Growth trend of market share of global bio-CMO industry in total global pharma CMO industry -----	131
Figure 26. Growth trend of global bio-API market -----	132
Figure 27. Distributions of each type of bio-APIs in total global bio-API market ---	132
Figure 28. Geographic distributions of global bio-API markets -----	133
Figure 29. Comparison of predicted growth rates of bio-API markets in some key regions of the world -----	134
Figure 30. Comparison of the market values of biogeneric APIs among China, India and the world -----	135
Figure 31. Existing issues and new development trends in global biopharma industry -----	143
Figure 32. Government plans to promote Chinese biopharma industry -----	151
Figure 33. Drivers for future development of Chinese biopharma outsourcing industry -----	166
Figure 34. Forecasted future growth trend of Chinese biopharma market -----	172
Figure 35. Forecasted future growth trend of Chinese therapeutic protein market ---	173
Figure 36. Forecasted future growth trend of Chinese vaccine market -----	174
Figure 37. Forecasted future growth trend of global vaccine market -----	175

### **List of Case Studies**

Case Study 1. Capability of a typical Chinese biopharma company -----	41
Case Study 2. Current capability of one of the best biopharma companies in China -	41
Case Study 3. Examples of biologic drugs developed by Chinese companies and recently approved for marketing in China -----	45
Case Study 4. A variety of vaccines are highly demanded in China -----	56
Case Study 5. Chinese-made biologics marketed in overseas markets -----	57
Case Study 6. Example of severity of viral infection and importance of vaccine development in China -----	67
Case Study 7. Examples of fast growth of sales revenue of Chinese vaccine producers -----	68
Case Study 8. Examples of major Chinese pharma companies getting involved in vaccine business -----	69
Case Study 9. GSK looking to the Chinese vaccine market -----	69
Case Study 10. Sanofi-Aventis expanding its presence in Chinese vaccine market ----	70
Case Study 11. Novartis entering Chinese vaccine market through acquisition of a Chinese vaccine maker -----	70
Case Study 12. Foreign companies marketing vaccines in China -----	71
Case Study 13. Examples of R&D approaches of Chinese biopharma companies in discovering innovative biologic drugs -----	89

Case Study 14. Example of high R&D productivity of Chinese biopharma companies -----	91
Case Study 15. China is the first country in the world that approved vaccines for H1N1 influenza -----	92
Case Study 16. R&D capability of a typical Chinese biopharma company -----	92
Case Study 17. More examples of Chinese biopharma company's R&D capability ---	93
Case Study 18. R&D collaboration between Chinese pharma companies and US biotech companies on development of new MAb drugs -----	94
Case Study 19. Chinese companies licensing drug candidates from Western companies and further developing them in China -----	94
Case Study 20. Example of current vaccine manufacturing capability of Chinese biopharma companies -----	103
Case Study 21. Chinese companies forming alliance to enhance their capability -----	106
Case Study 22. Experienced multinational companies forming JVs with their Chinese counterparts -----	106
Case Study 23. Major biopharma companies building bio-manufacturing capacity in both China and India: Another head-to-head comparison of biopharma industry between China and India -----	107
Case Study 24. Comparison of vaccine manufacturing methods between Chinese companies and its Western counterparts -----	111
Case Study 25. Genzyme outsourcing manufacturing of one of its gene therapy drugs to China -----	137
Case Study 26. Current manufacturing capability of one of the best bio-CMOs in the West -----	137
Case Study 27. Comparison of manufacturing capability and capacity between a typical Chinese bio-CMO and a typical Western bio-CMO -----	138
Case Study 28. Examples of fast development of biopharma industry in China -----	147
Case Study 29. Examples of VC investment in Chinese biopharma companies -----	149
Case Study 30. Multinational companies building MAb manufacturing facility in China -----	155
Case Study 31. Collaboration between Chinese biopharma companies and Indian counterparts in developing biologics -----	156
Case Study 32. Single use bio-processing equipment is penetrating Chinese biopharma industry -----	158
Case Study 33. Chinese biopharma companies developing new technology in RNA interference -----	159
Case Study 34. China is building the Asian largest stem cell storage and processing facility -----	162
Case Study 35. Examples of foreign biotech companies collaborating with local Chinese companies or independently developing technologies in stem cell research in China -----	163
Case Study 36. China is building the Asian largest biomanufacturing facility -----	167
Case Study 37. China is building more biopharma incubators -----	167
Case Study 38. China is building a large number of industrial parks for biopharma industry -----	168
Case Study 39. Chinese biopharma companies are enhancing their capability and	

capacity -----	168
Case Study 40. Recent quality issue with a vaccine product -----	169
Case Study 41. Chinese regulatory authority has stepped up and been tightening up the quality control -----	170